Researchers at Washington University School of Medicine in St. Louis published a study demonstrating that blocking a specific immune response pathway with a CXCR3 antibody reduces T cell brain infiltration by roughly half, preserving 40% more memory center tissue and improving memory performance in mice with Alzheimer’s-like tau accumulation.
In Plain English: The Clinical Takeaway
- Targeting the Immune System: Rather than attacking abnormal proteins directly, this experimental treatment blocks the brain’s inflammatory immune response, which growing evidence suggests causes the bulk of damage in tauopathies like Alzheimer’s.
- Peripherally Restricted Delivery: The therapeutic antibody successfully operates by binding to receptors at the border of the brain without needing to cross into the brain tissue.
- Preserving Brain Tissue: Treated animal models maintained approximately 40% more tissue in critical memory centers and scored better on cognitive evaluations, despite unchanged levels of toxic tau proteins.
How Immune Cells Drive Neurodegeneration in Tauopathies
There is currently no treatment available today to stop the death of brain cells in neurodegenerative conditions known as tauopathies. This broad category includes Alzheimer’s disease, marked by twisted clumps of a protein called tau. While cellular destruction typically clusters near these protein clumps, growing evidence suggests that much of the damage doesn’t come from the protein directly.
Instead, the immune system’s response to tau drives the progressive loss of memory and independence. Two existing Alzheimer’s drugs on the market—lecanemab and donanemab—focus on a protein called amyloid, which forms plaques between brain cells during early disease stages. While these anti-amyloid medications can slow a person’s decline, they have not been shown to keep brain cells from dying, and they do not work against primary tauopathies where amyloid never appears.
Mapping the T Cell Migration Route Through CXCR3 and CXCL10
Previous investigations led by the laboratory of David M. Holtzman established that activated T cells flood into regions of the brain dense with tau, triggering neurodegeneration. Subsequent research demonstrated that these T cells receive instructions within lymph nodes located outside the brain.
To navigate toward the brain, immune cells follow chemical trails known as chemokines. Investigators noted that the chemokine CXCL10 is elevated in tau-mouse models and that other groups had shown CXCL10 was elevated in Alzheimer’s. Because activated T cells carry a protein on their surface, CXCR3, that follows this particular trail, the research team identified this as the route used by immune cells to get into the brain.
Working alongside co-senior author Jason Ulrich and first author Joshua T. Emmerson, the research team examined mice lacking either the CXCL10 chemokine or the CXCR3 receptor. Without this, T cells failed to infiltrate the brain, even when researchers deliberately provoked inflammation to elicit an immune response.
Antibody Administration and Tissue Preservation Results
To test the approach, investigators administered a CXCR3-blocking antibody to young mice exhibiting tau accumulation prior to major brain cell loss. The treatment schedule involved injections every five days over a three-and-a-half-month period.
At the conclusion of the dosing regimen, treated subjects possessed roughly half the number of infiltrating T cells in their brains compared to untreated controls. Furthermore, treated subjects exhibited diminished nerve cell damage and greater preservation of regional brain tissue. Notably, tau tangles appeared the same in treated and untreated animals.
| Metric Measured | Untreated Control Group | CXCR3-Antibody Treated Group |
|---|---|---|
| Brain T Cell Infiltration | Baseline high | Reduced by approximately 50% |
| Memory Center Tissue Retention | Standard neurodegenerative loss | Retained roughly 40% more tissue |
| Intracellular Tau Tangle Levels | High | Unchanged compared to control |
| Cognitive Performance | Impaired | Improved relative to untreated cohort |
Analysis confirmed that the therapeutic antibody traveled to the border of each animal’s brain but not into the brain tissue. This discovery demonstrates that neurodegeneration can be treated without having to get a therapy into the brain itself.
Future Path for Clinical Development
“If we can show that we’re really decreasing brain cell death, it’s certainly worth trying to pursue that pathway to prevent the most devastating consequences of these diseases,” noted David M. Holtzman, the Barbara Burton and Reuben M. Morriss III Distinguished Professor in WashU Medicine’s Department of Neurology.
The findings, detailed in the journal Neuron, open an alternative therapeutic avenue focused entirely on dampening the destructive downstream immune response rather than solely attempting to clear anomalous protein deposits.
Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
